Haleon Pakistan 2025 Profit Jumps 39% to Rs6.4 Billion on Consumer Health Demand
Haleon Pakistan, the consumer health company behind brands like Panadol and Sensodyne, grew 2025 net profit 39 percent to Rs6.37 billion on 16 percent revenue growth and tight cost control. It declared a Rs15 per share dividend.
Haleon Pakistan, the consumer health business spun out of GlaxoSmithKline that owns household brands like Panadol and Sensodyne, had a strong 2025. Net profit rose 39 percent to Rs6.37 billion as demand for its over-the-counter medicines and oral care products grew and the company kept a tight grip on costs. It rewarded shareholders with a large dividend.
What the Haleon Pakistan 2025 results showed
Haleon Pakistan lifted net profit to Rs6.37 billion from Rs4.58 billion, with earnings per share rising to Rs54.45 from Rs39.11. Net revenue grew 16 percent to Rs43.11 billion, while cost of sales rose only 8 percent to Rs26.25 billion, a gap that shows real cost control and is why profit grew more than twice as fast as sales. Within the mix, the over-the-counter portfolio grew about 16 percent and the FMCG segment around 38 percent, led by oral health. The board declared a cash dividend of Rs15 per share.
| Measure | 2025 | 2024 |
|---|---|---|
| Net profit | Rs6.37bn | Rs4.58bn |
| Earnings per share | Rs54.45 | Rs39.11 |
| Revenue | Rs43.11bn | Rs37.21bn |
| Dividend | Rs15/share | n/a |
Why the result matters for consumer health stocks
Consumer health sits between pharma and FMCG. Like staples, its products are everyday purchases that hold up in weak economies, which makes demand defensive. But it also carries strong brands with pricing power, which supports margins. When revenue grows double digits and costs lag behind, as here, the operating leverage produces outsized profit growth. The combination of defensive demand, brand strength and cost control is what investors prize in this category.
Which stocks, and why
This is a direct, company specific result for Haleon Pakistan, and the read is clearly positive. A 39 percent profit rise on 16 percent revenue growth, with widening margins and a Rs15 dividend, is a high quality result built on real demand and efficiency rather than one off items. Strong brands in OTC and oral care give it a durable position, which is why the result lands as a solid positive.
What to watch
The signals to track are volume growth in the OTC and oral health portfolios, the cost of imported ingredients and the rupee, and any regulatory change to drug pricing, since part of the portfolio is medicines. Watch whether the company sustains its margin gains and dividend, and whether consumer demand holds as purchasing power shifts.
Frequently asked questions
How much did Haleon Pakistan earn in 2025?
Haleon Pakistan reported net profit of Rs6.37 billion for the year ended 31 December 2025, up 39 percent from Rs4.58 billion, with earnings per share of Rs54.45 and a Rs15 per share dividend.
What drove the growth?
Revenue rose 16 percent to Rs43.11 billion on strong demand for its over-the-counter and oral health products, while cost of sales rose only 8 percent, so margins widened and profit grew faster than sales.
Is the result positive for HALEON stock?
A 39 percent profit rise with a wider margin and a healthy dividend is a clearly positive result. This describes the company's performance and exposure, not a forecast for its share price.
Informational only — not investment advice. Sentiment reflects news exposure, not a buy/sell recommendation or price forecast. Do your own research and consult a licensed professional.
One story is a data point. The pattern is the edge.
Reading one story at a time, you miss how the news adds up. Track HALEON free and TradeTidings rolls every future headline into one clear positive, neutral or negative read, and alerts you the moment it turns.